Drug-Induced Liver Injury

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 2, 2004, Pages

  Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BROMFENAC; BUSULFAN; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; DANTROLENE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ERYTHROMYCIN; HALOTHANE; ISONIAZID; METHOTREXATE; METHYLDOPA; MINOCYCLINE; NEVIRAPINE; NITROFURANTOIN; PARACETAMOL; PHENYTOIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE; SULINDAC; TAMOXIFEN; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; DRUG;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; CHOLESTASIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONFERENCE PAPER; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; EOSINOPHILIA; FEVER; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; IMMUNE RESPONSE; LATENT PERIOD; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; STEATOSIS; TOXIC HEPATITIS; TOXICOGENOMICS; ARTICLE; CHEMICALLY INDUCED DISORDER; LIVER DISEASE; PATHOPHYSIOLOGY;

HEPATITIS, TOXIC; HUMANS; LIVER DISEASES; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 1542327565     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381446     Document Type: Conference Paper

References (27)

1. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24:483-90.
2. Zimmerman H. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 1999.
3. Pham T-V, Lu S, Kaplowitz N. Acetaminophen hepatotoxicity. In: Taylor MB, ed. Gastrointestinal emergencies. 2nd ed. Baltimore: Williams & Wilkins, 1997:371-88.
4. Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82:1826-32.
5. Thompson N, Caplin M, Hamilton M, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8:1384-8.
6. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22:137-44.
7. Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N, ed. Liver and biliary diseases. 2nd ed. Baltimore: Williams & Wilkins, 1996:103-20.
8. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000; 32:39-47.
9. Kaplowitz N. Mechanisms of cell death and relevance to drug hepatotoxicity. In: Drug-induced liver disease. Kaplowitz N, DeLeve LD, eds. New York: Marcel Dekker, 2002:85-95.
10. Kaplowitz N. Cell death at the millennium: implications for liver distress. Clin Liver Dis 2000; 4:1-23.
11. DeLeve L, Wang X, Kuhlenkamp J, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996; 23:589-99.
12. Odin JA, Huebert RC, Casciola-Rosen L, et al. Bcl-2-dependant oxidation. J Clin Invest 2001; 108:223-32.
13. Beune PH, Lecoeur J. Immunotoxicity of the liver: adverse reactions to drugs. J Hepatol 1997; 26(Suppl 2):37-42.
14. Robin MA, Le Roy M, Descatoire V, et al. Plasma membrane cytochrome P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26(Suppl 1):23-30.
15. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:467-86.
16. Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metab Rev 1990; 22:87-144.
17. Knowles S, Uetrecht J, Shear N. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 2000; 356:1587-91.
18. Uetrecht J. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger" hypothesis and innate immune system. Chem Res Toxicol 1999; 12:387-95.
19. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991-1045.
20. Tarazi EM, Harter JG, Zimmerman H, et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993; 104:569-74.
21. Moradpour D, Altorfer J, Flury R, et al. Chlorpromazine-inducing vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20:1437-41.
22. Ulrich R, Friend SH. Toxicogeneomics and drug discovery, will new technology produce better drugs? Nat Rev Drug Discov 2002; 1(1): 84-8.
23. DeLeve L, Kaplowitz N. Prevention and therapy of drug-induced hepatic injury. In: Wolfe M, ed. Therapy of digestive disorders. Philadelphia: WB Saunders, Harcourt, Brace, 2000:334-48.
24. Zimmerman H. Drug-induced liver disease. In: Schiff E, Sorell M, Madding W, eds. Schiff's diseases of the liver. 8th ed. Philadelphia: Lippencourt Raven, 1999:973-1064.
25. Loeper J, Descatoire V, Maurice M, et al. Presence of functional cytochrome P450 on isolated rat hepatocyte plasma membrane. Hepatology 1990; 11:850-8.
26. Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82:1826-32.
27. Kaplowitz N. Drug-induced liver disorders: introduction and overview. In: Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. New York: Marcel Dekker, 2002:1-13.